Drug Profile
Research programme: antimicrobials - Elitra/Incyte
Latest Information Update: 13 Sep 2006
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Mycoses
Most Recent Events
- 13 Sep 2006 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 13 Sep 2006 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 30 Apr 2003 Incyte Genomics is now called Incyte Corporation